UNSPSC 51433915: Felodipine

This classification denotes a calcium channel blocker with the molecular formula C18H19Cl2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OL961R6O2C, chemically known as 3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester but generally known as felodipine, which bears US NIH Compound Identifier 3333. European Medicines Agency schedules Felodipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11963MIG.

UNSPSC 51433915 Felodipine, a Commodity code, represents emergency and critical-care medications procured by state and local health agencies, fire and rescue departments, and multistate purchasing cooperatives. State and local governments buy this code to stock advanced life support (ALS) medications in emergency response vehicles, hospital formularies, and public health facilities. The scope encompasses individual medication line items supplied through wholesalers or direct-to-manufacturer channels, with stringent expiration-date and shelf-life requirements, cold-chain handling where applicable, and compliance with OSHA Hazard Communication Standards and FDA manufacturing practices. Issuing bodies span fire rescue departments (City of Tampa), state health commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance); these buyers typically procure in annual cycles with renewal options and reserve the right to split awards across multiple vendors based on clinical and supply-chain considerations.

Recent activity shows fragmented geographic distribution and mixed procurement mechanisms. The City of Tampa Fire Rescue posted a sealed-bid IFB (No. 26P00188) with a response deadline of April 8, 2026, seeking 370 units of Labetalol HCI, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem vials, with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered-market 5 percent bid discount. The Texas Health and Human Services Commission issued an exploratory RFI (No. HHS0017013) in April 2026 to evaluate direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling potential demand for manufacturer-direct supply relationships. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP (No. S1070000015802) with a March 26, 2026 response deadline for generic multi-source pharmaceuticals distributed across state and local government facilities in Minnesota and Oregon, requiring vendors to maintain relationships with three specified wholesalers (Cencora, Cardinal Health, Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act standards. Solicitations reflect state-level activity in Texas and Minnesota and municipal activity in Florida, with cooperative purchasing extending regional scope across participating jurisdictions.